SGP NASDAQ
SpyGlass Pharma, Inc. Common Stock
1W: +21.6%
1M: +10.5%
3M: +38.3%
YTD: +13.3%
$30.90
+0.99 (+3.31%)
After Hours: $31.55 (+0.65, +2.10%)
Weekly Expected Move ±7.8%
$24
$26
$28
$31
$33
Credit Risk of going bust: not rated Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0B
52W Range17.06-32.44
Volume89,398
Avg Volume120,387
Beta-0.89
Dividend—
Analyst Ratings
Company Info
CEOPatrick H. Mooney
Employees76
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-06
Websitespyglasspharma.com
15326 Alton Parkway
Irvine, CA 92618
US
Irvine, CA 92618
US
1 949 535 0588
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Latest News
SpyGlass Pharma acquires Advanced Vision Science
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Pharma, Inc. GAAP EPS of -$0.69
Recent Insider Trades
No insider trades found